CoronaryAtlas logo
CoronaryAtlas
ADAMTS13
Pathway / Endothelial activation & erosion

ADAMTS13

ADAMTS13protein

ADAMTS13 deficiency permits ultralarge VWF multimer accumulation, amplifying platelet adhesion and thrombotic risk in acute coronary events.

Pathway placement
Cascade stepEndothelial activation & erosion
Confidencehigh
RationaleVWF multimer-size regulator; endothelial dysfunction marker; imbalance drives platelet hyperadhesion.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000160323

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
67
C — non-Type-I
48
A — assay feasibility
72
E — evidence strength
69
T1DI (composite)
30
Specificity differential (R−C)+19.1
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 3
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 0
2hypoxemia / respiratory failuren/a
2hypertensive emergencymag 0
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 1
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 7/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 11 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Platelet-poor plasma
Collection tube
Sodium citrate 3.2% (light blue-top)
Method / principle
FRET-based activity assay
Reagent / substrate
FRETS-VWF73 fluorogenic substrate
Platform
Fluorometer / ELISA
Turnaround · availability
Send-out · Reference lab

Literature evidence(4)